| Clinical data | |
|---|---|
| Other names | NSC-43194; 4-Dehydrostanozolol; 17α-Methyl-2'H-androsta-2,4-dieno[3,2-c]pyrazol-17β-ol |
| Routes of administration | By mouth |
| Drug class | Androgen;Anabolic steroid |
| ATC code |
|
| Identifiers | |
| |
| CAS Number |
|
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C21H30N2O |
| Molar mass | 326.484 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Hydroxystenozole (INNTooltip International Nonproprietary Name), also known as17α-methylandrost-4-eno[3,2-c]pyrazol-17β-ol, is anorally activeandrogen/anabolic steroid (AAS) and a17α-alkylatedderivative oftestosterone that was described in the literature in 1967 but was never marketed.[1] It is closely related tostanozolol (17α-methyl-5α-androstano[3,2-c]pyrazol-17β-ol), differing from it only inhydrogenation (i.e.,double bonds and their placement).[1]
Thisdrug article relating to thegenito-urinary system is astub. You can help Wikipedia byexpanding it. |